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“ Coming together is a beginning; keeping together  
is progress; working together is success.”
Henry Ford
Created on May 5, 2010, the International Thymic Malignancy Interest Group (ITMIG) has doggedly pur-
sued its mission to advance clinical and basic science pertain-
ing to thymic and other mediastinal malignancies and related 
conditions. Progress in these rare diseases is sorely needed; 
without global collaboration progress is not possible, with-
out the creation of infrastructure collaboration is not feasible. 
ITMIG engaged the large majority of the global community 
active in thymic malignancies and developed a series of world-
wide standards, terms, and policies that established a common 
language. Many of these were published in a supplement to the 
Journal of Thoracic Oncology in 2011 (July 6; 7 Suppl 3).1–8 
This current supplement marks the next phase of building the 
infrastructure that permits collaboration and progress.
This supplement covers three main areas: (1) propos-
als for the first official stage classification system for thymic 
malignancies, based on analysis of an unprecedented global 
database; (2) guidance and standards papers to promote clini-
cal management and research in mediastinal tumors; and (3) 
“state of the science” reviews of relevant genetic, immuno-
logic, and systemic features of thymic malignancies.
The proposals for the first formal, validated, stage clas-
sification for thymic malignancies are presented as three 
manuscripts: an overview of the definitions and stage groups, 
details of the T descriptors and details of the N and M descrip-
tors. These proposals are the results of a global multispecialty 
effort, development of an unprecedented database of 10,808 
patients, and the participation of all major societies active in 
thymic malignancies (Table 1). The proposals were developed 
to inform the forthcoming eighth edition of the American Joint 
Committee on Cancer/Union for the International Cancer 
Control TNM classification of malignant tumors.
The “standards” section of this supplement addresses 
areas identified by the ITMIG education committee where 
clarity and consensus were needed. Development of these stan-
dards followed an established ITMIG process to create global 
consensus: formation of core workgroups to review existing 
information and draft proposals, refinement of these by extended 
workgroups, dissemination and solicitation of further feedback 
from the entire ITMIG membership, and finally approval of the 
final documents by the ITMIG membership (Table 2). These 
new standards include: “A Modern Definition of Mediastinal 
Compartments,” “A Proposed Lymph Node Map for Thymic 
Malignancy,” and “A Practical Guide from ITMIG Regarding 
the Radiographic Assessment of Treatment Response of Thymic 
Epithelial Tumors using Modified RECIST Criteria.”
Additionally, the education committee developed three 
manuscripts to provide guidance in clinical care. Specifically 
these address issues faced by clinicians and radiologists in 
evaluating a patient with an anterior mediastinal mass, and a 
practical guide for pathologists in evaluating thymoma. While 
these are not “standards,” they provide a platform and struc-
ture for those on the front lines caring for patients with rare 
conditions; these were developed and refined by workgroups 
and extended workgroups of experts.
The last section addresses topics that are highly relevant 
to care and research but are less well known. Many of these 
were highlights at the fourth Annual ITMIG Conference in 
Bethesda, September 2013. A better understanding of what 
is known about genetic alterations in thymic malignancy, and 
the interactions between these tumors and the immune system 
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TABLE 1.  Organizations Contributing to the Proposals for 
Stage Classification
ChART Chinese Alliance for Research in the Thymus
CRAB Cancer Research And Biostatistics
ESTS Thymic  
Group
European Society of Thoracic Surgeons—Thymic Group
IASLC International Association for the Study of Lung Cancer
ITMIG International Thymic Malignancy Interest Group
JART Japanese Association for Research in the Thymus
TABLE 2.  ITMIG Membership Approval Rating of Proposed 
New Global Standards
Topic % Approvala
CT-based Classification of Mediastinal Compartments 96
Mediastinal Node Map for Thymic Malignancies 90
Radiographic Assessment of Response to Therapy 97
aPercentage of ITMIG members approving the adoption of the proposed standards.
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is important to guide further research. Additionally, thymic 
malignancies have significant physiologic effects and interac-
tions with other organ systems. A wider appreciation of these 
can promote better clinical care as well as stimulate research 
to elucidate the underlying mechanisms
We thank those directly involved in the creation of these 
manuscripts as well as ITMIG membership for helping shape 
them to their final form. This entire work is a testament to what 
ITMIG has always stood for: an international collaboration 
to promote a scientifically based approach and facilitate dis-
semination of knowledge about thymic malignancies and other 
mediastinal diseases, in order to improve patient outcomes.
REFERENCES
 1. Detterbeck FC, Moran C, Huang J, et al. Which way is up? Policies and 
procedures for surgeons and pathologists regarding resection specimens 
of thymic malignancy. J Thorac Oncol 2011;6:S1730–S1738.
 2. Detterbeck FC, Nicholson AG, Kondo K, Kondo K, Van Schil P, Moran 
C. The Masaoka-Koga stage classification for thymic malignancies: clari-
fication and definition of terms. J Thorac Oncol 2011;6:S1710–S1716.
 3. Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ. Chemotherapy 
definitions and policies for thymic malignancies. J Thorac Oncol 
2011;6:S1749–S1755.
 4. Gomez D, Komaki R, Yu J, Ikushima H, Bezjak A. Radiation therapy defi-
nitions and reporting guidelines for thymic malignancies. J Thorac Oncol 
2011;6:S1743–S1748.
 5. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr. Standard outcome mea-
sures for thymic malignancies. J Thorac Oncol 2011;6:S1691–S1697.
 6. Marchevsky A, Marx A, Strobel P, et al. Policies and reporting guide-
lines for small biopsy specimens of mediastinal masses. J Thorac Oncol 
2011;6:S1724–S1729.
 7. Marom EM, Rosado-de-Christenson ML, Bruzzi JF, Hara M, Sonett JR, 
Ketai L. Standard report terms for chest computed tomography reports 
of anterior mediastinal masses suspicious for thymoma. J Thorac Oncol 
2011;6:S1717–S1723.
 8. Toker A, Sonett J, Zielinski M, Rea F, Tomulescu V, Detterbeck FC. 
Standard terms, definitions, and policies for minimally invasive resection 
of thymoma. J Thorac Oncol 2011;6:S1739–S1742.
